Evidence map›Paper›PMID 39516321›Full record

ArticleBJC reports2024

Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.

Masaki Shiota, Nobuaki Matsubara, Taigo Kato, Masatoshi Eto, Takahiro Osawa, Takashige Abe, Nobuo Shinohara, Koshiro Nishimoto, Yota Yasumizu, Nobuyuki Tanaka and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJC reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Circulating Tumor DNA Genomic Profiling inJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Observational
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Masaki ShiotaDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Kyushu, Japan. shiota.masaki.101@m.kyushu-u.ac.jp.
Nobuaki MatsubaraDepartment Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
Taigo KatoDepartment of Urology, Osaka University Graduate School of Medicine, Yamadaoka, Japan.
Masatoshi EtoDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Kyushu, Japan.
Takahiro OsawaDepartment of Urology, Graduate School of Medicine Hokkaido University, Hokkaido, Japan.
Takashige AbeDepartment of Urology, Graduate School of Medicine Hokkaido University, Hokkaido, Japan.
Nobuo ShinoharaDepartment of Urology, Graduate School of Medicine Hokkaido University, Hokkaido, Japan.
Koshiro NishimotoDepartment of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Yota YasumizuDepartment of Urology, Keio University School of Medicine, Tokyo, Japan.
Nobuyuki TanakaDepartment of Urology, Keio University School of Medicine, Tokyo, Japan.
Mototsugu OyaDepartment of Urology, Keio University School of Medicine, Tokyo, Japan.
Takao FujisawaDepartment Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
Satoshi HorasawaTranslational Research Support Office, National Cancer Center Hospital East, Chiba, Japan.
Yoshiaki NakamuraDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
Takayuki YoshinoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
Norio NonomuraDepartment of Urology, Osaka University Graduate School of Medicine, Yamadaoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCirculating tumor DNA (ctDNA) testing has emerged as a novel tool for cancer precision medicine. This study investigated the genomic profiling and clinical utility of ctDNA in metastatic prostate cancer.

methodsThis is a nation-wide prospective observational study. Patients treated with systemic treatment for metastatic castration-sensitive prostate cancer (mCSPC) and metastatic castration-resistant prostate cancer (mCRPC) were included. ctDNA was analyzed using FoundationOne Liquid®CDx at enrollment. In a subset of patients, ctDNA after disease progression and tissue prior to the initiation of treatment were examined using FoundationOne Liquid®CDx and FoundationOne®CDx, respectively.

resultsThe frequency of AR alterations and homologous recombination repair (HRR) defect was higher in mCRPC compared with mCSPC. Tumor mutational burden was correlated between tissue and ctDNA at pre-treatment, as well as ctDNA between at pre-treatment and at post-treatment. Patients with HRR defect were associated with shorter time to castration resistance in androgen deprivation therapy/combined androgen blockade, but not in androgen receptor pathway inhibitor, compared with patients without HRR defect in mCSPC. Time to treatment failure in patients with AR amplification or AR mutation was shorter compared with patients without AR alterations in mCRPC.

conclusionsThis study revealed valuable findings for the clinical care of metastatic prostate cancer. Especially, predictive factors such as HRR defect in mCSPC should be validated in the future.

Identifiers

PMID39516321
PMCPMC11523993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.